Clinical Study
Renal Function and NODM in De Novo Renal Transplant Recipients Treated with Standard and Reduced Levels of Tacrolimus in Combination with EC-MPS
Table 1
Demographic and baseline characteristics between the treatment groups (ITT population).
| | | Low-dose Tac group
(Group A) () | Standard-dose Tac group
(Group B) () |
| | Age (years) | 47.7 ± 12.6 | 45.3 ± 12.9 | | Men (%) | 72.2 | 65.2 | | Race (%) | | | | Caucasians | 88.1 | 83.0 | | Blacks | 4.6 | 10.6 | | Asians | 4.6 | 3.5 | | Others | 2.7 | 2.9 | | Time on dialysis (months) | 30.6 ± 28.4 | 30.4 ± 27.1 | | Donor/recipient CMV serological status (%) | | | | Negative/negative | 17.9 | 16.3 | | Negative/positive | 19.9 | 20.6 | | Positive/negative | 13.2 | 12.8 | | Positive/positive | 43.7 | 48.2 | | Donor age (years) | 42.7 ± 14.1 | 42.0 ± 13.9 | | Donor type (%) | | | | Donation after brain death | 69.5 | 67.4 | | Living related | 18.5 | 23.4 | | Living unrelated | 11.9 | 9.2 | | Number of HLA mismatches (%) | | | | 0 | 2.0 | 2.8 | | 1–3 | 44.4 | 46.8 | | 4–6 | 53.6 | 50.4 | | Cold ischemia time (h) | 13.6 ± 9.1 | 12.0 ± 8.9 | | PRA < 20% (%) | 97.4 | 98.6 |
|
|
CMV: cytomegalovirus; HLA: human leukocyte antigen, PRA: panel reactive antibodies.
Results expressed as mean ± standard deviation (SD) unless otherwise indicated.
|
